Skip to main content

Table 2 Patient characteristics

From: Achievement of renal anemia KDIGO targets by two different clinical strategies – a European hemodialysis multicenter analysis

 

All

Portugal

Poland

p*

(%)

(%)

(%)

Hemoglobin 10–12 g/dL

67.3

65.8

69.5

N.S.

Hemoglobin > 12 g/dL

15.2

15.3

15.1

N.S.

Ferritin ≥200 μg/L

84.4

82.9

86.6

N.S.

Ferritin ≥800 μg/L

24.0

15.8

35.6

<  0.001

TSAT ≥20%

81.5

76.3

88.8

<  0.001

TSAT ≥50%

9.4

5.7

14.6

<  0.001

Treatment with ESA

76

78

74

0.056

Type of ESA

N.S.

 Darbepoietin

24

22

26

 Epoetin beta

76

78

74

Route of ESA administration

<  0.001

 Intravenous

64.5

99.8

11.5

 Subcutaneous

35.5

0.2

88.5

ESA administration, frequency

<  0.001

 No ESA

23.6

21.7

26.3

 Every other week

0.4

0.7

0

 Once per week

15.0

2.1

33.2

 Twice per week

15.9

11.1

22.6

 Three times per week

45.1

64.5

18.0

Dialysis modality

<  0.001

 HDF

46.6

91.4

0

 HD

53.4

8.6

100

spKt/V > 1.2

97.3

98.5

95.6

0.003

URR ≥ 70%

90.8

95.4

84.4

<  0.001

Treatment time ≥ 12 h/week

93.8

94.0

93.6

N.S.

Prescribed Qb ≥ 300 mL/min

94.1

97.4

89.4

<  0.001

Treated blood volume ≥ 1 L/kg body weight

90.0

95.7

81.9

< 0.001

CVC (%)

16.5

14.5

19.3

0.026

AV Fistula (%)

76.8

77.1

76.4

N.S.

S-Albumin ≥35 g/L

89.7

95.4

81.8

< 0.001

Charlson comorbidity index

< 0.001

  < 7

44.5

39.1

52.1

 7–12

51.9

56.7

45.2

  > 12

3.6

4.3

2.7

Diabetes mellitus

26

30

25

N.S.

Phosphorus ≤5.5 mg/dL

82.0

87.5

74.2

< 0.001

Calcium ≤10.2 mg/dL

98.1

98.0

98.2

N.S.

PTH 150–600 pg/mL

53.9

52.1

56.4

N.S.

  1. * Chi-2 analysis between countries